Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-MAPB + 6-APB
- Development stage
- Preclinical
- Lead developer
- Clearmind Medicine
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intranasal, Rectal, Transdermal, Inhalation
01
Overview
5-MAPB + 6-APB is a preclinical-stage small molecule drug combination being developed by Clearmind Medicine for use in drug-assisted psychotherapy. The combination consists of two benzofuran-class entactogens: 5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) and 6-APB (6-(2-aminopropyl)benzofuran). These compounds are structurally and pharmacologically related to MDMA and act as triple monoamine reuptake inhibitors and releasing agents, targeting the serotonin, dopamine, and norepinephrine systems. Clearmind is investigating this combination as a potential 'fail-safe' or alternative to MDMA-assisted psychotherapy, particularly for patients who have developed tolerance to MDMA or for whom MDMA therapy is ineffective or inappropriate. Primary targeted indications include post-traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and relational or relationship-based psychological distress.
- Other names
- 5-MAPB + 6-APB5MAPB & 6APB5-MAPB and 6-APB
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on 5-MAPB + 6-APB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-MAPB + 6-APB.